Share on LinkedInShare on LinkedIn

ARTICLE · 06 JULY 2009

SJ Berwin´s Community Week: A Weekly Summary Of Competition Law And Policy Developments Issue 430 3 July 2009

In 1998 GlaxoSmithKline introduced a dual pricing system in Spain with a view to deterring parallel trade.

United KingdomAntitrust/Competition Law
SJ Berwin'S EU & Competition Team
SJ Berwin'S EU & Competition Team

EU DEVELOPMENTS

Advocate General criticises CFI Reasoning In GlaxoSmithKline Parallel Imports Case

In 1998 GlaxoSmithKline ("GSK") introduced a dual pricing system in Spain with a view to deterring parallel trade.  Intermediaries in Spain were offered different prices for pharmaceutical products, depending on whether they intended to sell the products within Spain or to other EEA countries, with higher prices charged for export products. 

In May 2000 the European Commission ("Commission") determined that this dual pricing system infringed Article 81 EC by both object and effect, and that GSK had failed to establish that it met the requirements for exemption under Article 81(3) (specifically failure to prove a contribution to the promotion of technical progress).  GSK challenged the Commission's decision on a number of grounds. 

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from